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Abstract
Introduction: Parkinson’s disease is neurodegenerative disorder characterized by the loss of
striatal  dopaminergic  neurons.  Besides  the  improvement  of  the  dopaminergic  loss,  the
treatment focuses on non-dopaminergic medication targeting motor and non-motor symptoms,
and on the development of neuroprotective medication. A good knowledge of the properties of
the compounds used is essential not only for those involved in pharmacological research, but
also for those who treat Parkinson’s disease patients, facing their still many unmet needs.
Areas covered: The review discusses the pharmacokinetic properties of levodopa, and factors
influencing  them,  the  pharmacodynamics  of  levodopa  and  approaches  with  the  aim  of
improving this, covering some of the other antiparkinson medication available. Among the
non-dopaminergic agents, it focuses on research on kynurenines. A literature search was made
in  Pubmed  for  Parkinson’s  disease  treatment,  levodopa,  levodopa  absorption,  levodopa
pharmacokinetics, continuous dopaminergic stimulation,  levodopa-carbidopa intra-intestinal
gel therapy, dopamine agonists, monoamine oxidase-B inhibitors and kynurenines. 
Expert opinion: Various factors can cause irregularities in the pharmacokinetics of levodopa,
with interconnected consequences on its  therapeutic effect.  Its  long-term use is  associated
with the development of motor complications; this is explained mostly by pharmacodynamic,
but  also  by pharmacokinetic  properties,  the  latter  gaining  in  importance  in  the  advanced
stages of the disease. 
Introduction
Parkinson’s  disease  (PD)  is  the  second  most  frequent  neurodegenerative  disorder
following Alzheimer’s disease. The incidence rises stepwise with increasing age, to 93.1 in
100,000  person  years  between  70  and  79  years  of  age  [1].  PD  is  characterized  by  a
progressive loss of dopaminergic cells in the substantia nigra (SN) pars compacta. The motor
symptoms of the disease include tremor, rigidity, bradykinesia and postural instability. Non-
motor symptoms can manifest even in the early stages of the disease and have a great impact
on the quality of life (see Table 1). The non-dopaminergic pathways also play a role in their
occurence.
For decades, treatment has focused on correcting the dopaminergic loss and thereby
alleviating the cardinal motor symptoms of the disease.  There is  growing interest  in non-
dopaminergic medication that moderates the motor and non-motor symptoms and dyskinesias.
In  addition  to  symptomatic  treatment,  efforts  are  being  made  to  develop  putative
neuroprotective medication capable of preventing the progression of the disease. 
Article highlights
  The characteristics of the pharmacokinetics of levodopa are a short T1/2, absorption
through active transport in the small intestine and at the BBB, an extensive peripheral
metabolism and renal elimination of the metabolites. 
 The absorption of levodopa is influenced by delayed gastric emptying, competition for
the absorption sites in the small bowel and infections occurring in the GI tract, such as
SIBO and HP infection. 
 In the advanced stages of the disease, the fluctuating plasma dopamine levels can not
be  buffered  by  the  decreasing  number  of  functional  dopaminergic  neurons  and
dopaminergic stimulation becomes dependent on the plasma levodopa level. 
 LCIG  therapy  provides  more  continuous  absorption  and  consequently  steadier
levodopa blood levels, but has several limitations.
 As  compared  with  levodopa,  DAs  have  a  longer  T1/2 and  a  more  stable
pharmacokinetic profile. Among DAs, the apomorphine pump, transdermal rotigotine
and  ER  formulations  are  approaches  through  which  to  provide  a  more  constant
stimulation of the dopamine receptors.
           Among non-dopaminergic medication, neuroactive kynurenines could provide a 
           neuroprotective effect in patients with PD. 
 
I. Levodopa 
Since its introduction in the 1960s, in spite of the therapeutic challenge of the motor
complications  (MCs)  that  emerge  in  time,  levodopa  (LD)  remains  the  best  symptomatic
treatment,  and is  the gold standard of the therapy of PD. A number of factors can cause
irregularities in the absorption, distribution, metabolism, excretion and toxicity (ADMET) of
LD, with consequences on the therapeutic effect. The introduction of LD was followed by the
development  of  inhibitors  of  dopamine-metabolizing  enzymes  and  dopamine  receptor
agonists  in  order  to  lower  the  risk  of  MCs  and  to  provide  better  symptomatic  control.
Different formulations of LD, such as controlled or extended-release (ER) preparations and
new approaches,  such as  levodopa-carbidopa intra-intestinal  gel  (LCIG)  therapy,  are  also
available. 
1. Pharmacokinetics of levodopa
LD is a prodrug, a dopamine precursor. In order to exert its antiparkinsonian effects,
several steps are needed, such as gastrointestinal (GI) absorption, passage across the blood-
brain barrier (BBB), neuronal uptake, enzymatic conversion to dopamine through an aromatic
amino  acid  decarboxylase  (AADC),  and  synaptic  release.  This  chapter  outlines  the
characteristics of the pharmacokinetics of LD and the factors on which it depends. Long-term
therapy causes no substantial changes in the peripheral pharmacokinetics of LD, but leads to
changes  in  the  central  pharmacokinetics  and  pharmacodynamics  responsible  for  the
development of LD-related MCs. Accordingly, the peripheral pharmacokinetics becomes of
greater importance in more advanced stages of disease [2]. 
1.1. Absorption of levodopa and factors influencing it 
LD itself is unable to cross the BBB. It is actively transported through the intestinal
wall  and the BBB by an amino acid transporter for large neutral  amino acids.  When co-
administered with an AADC, it is rapidly absorbed, with a bioavailability of 84-99% for oral
administration [3]. The rate of absorption depends on the gastric pH, on the rate of gastric
emptying,  and on the time during which  the  drug is  exposed to  the gastric  acid and the
intestinal  flora  containing  the  degrading  enzymes.  Absorption  may  be  impaired  by
hyperacidity of the gastric juice,  delayed gastric emptying and competition for absorption
sites in the small intestine. These factors are also interrelated. In this respect, excessive gastric
acidity can delay gastric emptying. On the other hand, excessive neutralization of the gastric
acidity leads to the incomplete dissolution and absorption of LD tablets [2, 4]. 
1.1.1.  Delayed gastric  emptying (DGE): Low gastric  motility and constipation  are
characteristic non-motor symptoms of PD and lead to DGE [5], especially in PD patients with
motor  fluctuations  [6].  The  stimulation  of  gastric  dopamine  receptors  also  depresses  the
gastric motility. DGE triggers an extensive metabolism that results in less LD being available
for absorption. Gastric emptying contributes to a varying plasma LD level and bioavailability,
which influences the delivery of LD to the brain and ultimately the motor response [7]. It has
been  shown  that  erratic  absorption  contributes  to  pulsatile  stimulation  of  the  striatal
dopaminergic receptors, which results in time in dyskinesias and MCs. DGE delays and blunts
the peak LD concentration (Cmax), leading to a delay or failure of the clinical response. A
delayed-on phenomenon  emerges,  or  in  more  severe  cases  no-on occurs,  when  no
symptomatic effect can be seen, or the unpredictable  off phenomenon [2,6]. DGE and slow
intestinal motility favor the occurrence of local infections, which can further diminish the
absorption and influence the clinical response [8]. 
The  efficiency  of  gastric  emptying  can  be  improved  by  the  withdrawal  of
anticholinergic drugs and the relief  of constipation with a high-fiber  and fruit  diet,  oil  or
lactulose [2]. Domperidon can be added to LD preparations in order to minimize this problem.
The absorption of LD is better from orally disintegrable tablets, such as dispersible, methyl-
ester or ethyl-ester preparations [9]. The Cmax is then earlier  reached and the clinical effect
more predictable and reliable [10,  11].  An intra-intestinal  preparation avoids the unsteady
absorption seen with oral formulations.
Table 1. Non-motor symptoms of PD
Neuropsychiatric symptoms
 depression
 psychosis
 anxiety
 fatigue
 impulse control disorder
 cognitive impairment
 dementia
Autonomic symptoms
 drooling
 increased sweating
 gastrointestinal dysfunction
 constipation
 bladder dysfunction
 orthostatic hypotension
 sexual dysfunction
Sleep disorder
 REM sleep behavior disorder
 vivid dreams
 restless legs syndrome
 insomnia
 excessive daytome sleepiness
Sensory symptoms
 anosmia
 pain
 paresthesia
REM: rapid eye movement
1.1.2. Infectious agents: It has been demonstrated, that infection with  Helicobacter
pylori (HP), or gastritis  with some other etiology, can diminish the absorption of LD and
influence motor fluctuations. In some studies, HP infection was found to be more prevalent in
PD patients than in healthy controls [12, 13], though this finding was not verified in other
studies [14]. HP infection was associated with the  no-on and  wearing-off phenomena and a
higher prevalence of unpredictable motor fluctuations; eradication of HP infection improved
the absorption of LD [12, 13]. In a more recent study investigating the effect of HP infection
on the clinical response to LD, no higher prevalence of motor fluctuations was found with HP
infection.  27% of  the  75  PD patients  included were  HP infected.  Wearing  off  and sleep
disturbance were significantly less common among them; no significant difference in the LD
equivalent doses was seen. Authors concluded that the less symptom fluctuation might be due
to an altered absorption of LD in the HP infected patients [15]. There is a connection between
small intestinal bacterial overgrowth (SIBO) and HP infection, because HP causes atrophic
gastritis  with  hypoacidity,  predisposing  to  SIBO  [16].  The  contribution  of  SIBO  to  the
pathophysiology  of  motor  fluctuations  was  investigated  in  a  study.  SIBO  was  found
significantly higher  in  PD patients  compared to  controls,  but  HP infection was not  more
prevalent.  Patients  with such infectious  conditions  displayed a  significantly longer  gastric
emptying time, a higher prevalence of unpredictable motor fluctuations, a longer off time, and
more  delayed-on and  no-on.  Eradication of  the infection improved the motor  fluctuations
without affecting the pharmacokinetics of LD [14].
1.1.3.  Competition  for  absorption  sites:  Absorption  depends  on  protein  intake,  as
proteins act as competitive inhibitors of the active carrier through the intestinal wall and the
BBB [17]. Even though they avoid high-protein meals, many patients do not experience the
expected on mobility. According to some authors, this might be influenced by the presumption
that more LD is required when patients are physically active [2]. In order to minimize the
effects of proteins on its absorption, the intake of LD should be recommended before meals or
with a low-protein intake [18]. 
1.1.4. Nicotine: The pharmacokinetics of LD is influenced by nicotine. Nicotine used
as a patch or gum can improve the symptoms of PD, as revealed for nicotine gum in juvenile
PD patients  [19]. In mouse models, nicotine improved LD-related dyskinesias  [20], and the
same was found for nicotinic receptor agonists in a monkey model [21]. Clinical studies of the
effects of nicotine on PD symptoms have led to contradictory conclusions. In a relatively
recent study, some motor worsening was seen after nicotine was administered with or without
LD, irrespective of LD intake [22]. A subthreshold stimulation of the presynaptic D2 receptors
by a  low nicotine concentration was considered to  be responsible  for the transient  motor
worsening. A high-dose nicotine patch and chronic intravenous nicotine treatment followed by
patch  use  improved  the  motor  and  the  motor  and  cognitive  symptoms  of  PD  patients,
respectively.  In  the  intravenous  approach  followed  by patch  administration,  the  response
lasted even after cessation of the therapy [23, 24]. In an earlier study, nicotine patch was not
effective  [25]. In healthy subjects, nicotine did not influence the gastric emptying, while in
those smoking high-dose nicotine cigarettes the gastric emptying was delayed relative to that
in those smoking low-dose nicotine cigarettes. In a study of the effects of nicotine on the
pharmacokinetics of LD, Cmax and the area under the plasma concentration-time curve from 0
to 4 hours for LD did not differ significantly in patients using a nicotine patch and controls.
The difference in the plasma concentration of LD between Cmax and 30 min after Cmax was
reduced in the nicotine patch group as compared with the controls. The mean plasma LD
concentration  was  significantly  lower  in  the  nicotine  patch  group.  The  plasma  LD
concentration curve was smoother during nicotine treatment.  No significant  differences in
gastric emptying were seen between the two groups as measured by the 13CO2 breath test. In
cultures on Caco-2 cells, nicotine reduced the amount of permeated LD, by as much as 25%.
Nicotine  stimulates  endogenous  dopaminergic  synthesis  and  as  a  result  may  modulate
dopaminergic neurotransmission [26]. 
1.2. Distribution of levodopa
The plasma LD concentration peaks at 0.5-2 h after an oral dose. The plasma half-life
(T1/2) is short, at 36-96 min  [17]. The Cmax and T1/2 of LD influence the therapeutic effect,
more  markedly in  the  advanced stages  of  the  disease.  According to  a  study a  long term
therapy increases Cmax and decreases T1/2 [27]. Taking LD after a meal can extend the duration
of its  efficacy.  When LD is taken after  a  meal  Cmax is  decreased and T1/2 is  increased as
compared with taking it before meals; therefore, taking LD after a meal might extend the
effective time and decrease the dyskinesia [28]. LD is distributed to most tissues. Less reaches
the cerebral circulation in an unchanged form and only about 1% of the ingested drug reaches
the  central  nervous  system,  due  to  its  extensive  peripheral  metabolism  [29].  Adding  a
peripheral AADC (carbidopa or benserazide) considerably elevates the level of LD entering
the CNS and controls  side-effects  due to  peripheral  decarboxylation,  such as  vomiting or
nausea. All LD compounds, including oral and intraintestinal formulations, therefore contain
an AADC inhibitor. 
Figure 1: Absorption and metabolism of levodopa. 
BBB:  blood-brain  barrier,  CNS:  central  nervous  system,  COMT:  catechol-O-methyl
transferase,  DA:  dopamine,  DOPAC:  3,4-dihydroxyphenylacetic  acid,  HVA:  homovanillic
acid, L-DOPA: levodopa, MAO-B: monoamine oxidase B, 3-MT: 3-methoxytyramine, 3-O-
MD: 3-O-methyldopa, R: dopamine receptors, SIBO: small intestinal bacterial overgrowth.
Discontinuous arrow: inhibition 
1.3. Metabolism of levodopa
The  metabolism  of  LD  occurs  in  the  GI  tract  and  in  the  brain  (Figure  1).  The
enzymatic modification of LD is a result of the action of dopa- or AADC, monoamine oxidase
B (MAO-B) and catechol-O-methyl transferase (COMT). In the periphery, the extracerebral
AADC breaks down about 95% of the total LD to dopamine. The drug is also decarboxylated
during the first passage through the liver. A smaller amount undergoes methylation to 3-O-
methyldopa in the GI tract, due to COMT activity. When it is administered alone, the main
metabolic route is decarboxylation, whereas when it is administered with an AADC inhibitor,
the main metabolic pathway is the formation of 3-O-methyldopa. Methyldopa has a 10 times
longer half-life than that  of LD and it  exhibits  a high plasma concentration after  chronic
treatment [30]. Although it can theoretically compete with LD for active transport sites across
the BBB, it does not alter the transport of LD [31]. 
The result of its peripheral metabolism is a lower level of LD entering the brain and an
increased blood dopamine level. Dopamine is a catecholamine that acts on alpha and beta-
adrenergic receptors and is responsible for the toxic effects of LD. LD crosses the BBB, and is
taken up by the dopaminergic neurons, where it is decarboxylated to pharmacologically active
dopamine  in  the  presynaptic  terminals  of  the  basal  ganglia.  The  addition  of  an  enzyme
inhibitor  reduces  its  peripheral  metabolism  and  improves  its  bioavailability.  Among  the
peripheral  decarboxylase  inhibitors,  carbidopa  has  a  variable  and  slow  absorption  as
compared with that of LD and a longer T1/2 in consequence of which its plasma concentration
stabilizes later. It is presumed to have a different mechanism of transport. 
The  addition  of  COMT inhibitors to  LD increases  the  bioavailability  of  LD,  and
extends its T1/2 [28], but does not increase the time to Cmax, nor the Cmax [32]. According to
other studies Cmax was significantly higher after the addition of a COMT inhibitor [33]. 
As a result, more LD is delivered across the BBB over a longer time and more LD
enters the brain and reaches the striatum, where it is converted to dopamine. Preclinical trials
showed  less  dyskinesia  and  fewer  motor  fluctuations  following  the  entacapone-LD
combination than after LD alone  [34]. Clinical trials  supported these observations (FIRST
STEP study) [35], but did not prove that the LD/carbidopa/entacapone combination can delay
dyskinesia as compared with LD/carbidopa; in fact the opposite was proven, that dyskinesias
developed  earlier  and  more  with  addition  of  entacapone  (STRIDE-PD  study)  [36].  The
COMT inhibitors tolcapone and entacapone are recommended in clinical practice for patients
who  exhibit  the  wearing-off phenomenon.  The  side-effects  of  COMT inhibitors  include
diarrhea,  signs  of  excessive  dopaminergic  stimulation,  and hepatic  necrosis  for  tolcapone
[37]. Though not substantial, some changes in pharmacokinetics can be seen in association
with  long-standing LD therapy.  There  may be  an  accelerated  metabolism due to  enzyme
induction, a decrease in the T1/2 of LD and an increased Cmax [28]. 
1.4. Elimination of levodopa
There are several dozen metabolites, but the main urinary excretion products are 3-4-
dihydroxy  phenylacetic  acid  (DOPAC)  and  3-methoxy-4-hydroxy  phenylacetic  acid
(homovanillic  acid,  HVA).  These  account  for  50% of  the  administered  dose.  HVA alone
accounts for 13-42% of the ingested LD dose [29]. As much as 80% of a radioactively labeled
dose is excreted in the urine and recovered within 24 h. Only small amounts are excreted
through the feces. In time, after long-standing LD therapy, the amounts of DOPAC and HVA
excreted  increase,  presumably  due  to  a  depletion  of  the  methyl  donors  needed  for  the
metabolism by COMT [31].
1.5. Toxicity of levodopa
The side-effects  of  LD (Table  2)  [38,  39] are  usually reversible  when the  dose is
decreased or the drug is withdrawn, but there have been several reported cases of toxicity and
even fatality due to LD overdoses. No data are available concerning the mutagenicity of LD.
Carcinogenicity has not been proved, but there have been concerns regarding the activation of
melanomas,  though  these  have  not  been  proved  either.  As  to  teratogenicity,  it  has  been
demonstrated in rabbits that LD causes visceral and skeletal malformations in the offspring.
No relevant data are available on humans [31, 40].
The most troublesome feature,  with a negative impact on the quality of life of the
patient, are the MCs that develop in time, such as choreiform and/or dystonic movements,
variable in morphology, involving eyes, head, trunk or extremities. Their frequency increases,
as the drug administration continues and are related to the doses administered. They occur in
up to 10% of the patients per year with each year of therapy, or in about 50% of the patients
after 5 years of therapy and in almost 100% after 10 years  [2, 41]. Dyskinesias have been
reported to have an incidence ranging from 8% to 64% of the patients after  4-6 years of
therapy [42].
Sudden  LD  withdrawal  can  lead  to  a  neuroleptic  malignant-like  syndrome  with
akinesia, rigidity, fever and autonomic disturbances. Drug interactions (Table 3) can influence
the metabolism of LD and thereby its side-effects. Long-standing treatment interferes with the
metabolism of vitamin B12, folate and homocysteine, leading to an increase in homocysteine
levels and deficiencies of vitamin B12 and folate [43]. 
1.5.1.Concerns of LD toxicity
A few years after the discovery of LD and its introduction in clinical practice, a debate
arose concerning its toxicity [44, 45]. The concerns were based on the development of MCs
after  some  years  of  treatment  and  the  presumption  that  LD  might  accelerate  neuronal
degeneration through free radicals generated by its oxidative metabolism. There are increased
Fe++,  decreased  glutathione  and  increased  malondialdehyde  levels  and  a  decreased
mitochondrial complex I activity in the SN of PD patients, suggesting that free radicals play a
role in the pathological processes and apoptosis of midbrain dopaminergic neurons [44, 46].
H2O2, the precursor of the toxic hydroxyl radical, is a product of dopamine metabolization via
MAO. In the surviving neurons there is an increased rate of metabolism, with further free
radical formation. LD was therefore proposed as second-line therapy. In the ELLDOPA trial,
which compared different doses of LD with placebo in patients with early PD, the results
suggested that it is not toxic, but may in fact be neuroprotective  [47], and that it does not
accelerate the progression of PD and can be recommended at an early stage of the disease [44,
48-50].
2. Pharmacodynamics of LD and clinical implications
The  antiparkinsonian  effect  of  LD  relies  on  the  synthesis  of  dopamine  and  its
interaction  with  the  dopamine  receptors.  The  efficacy  of  LD  varies  due  to  factors  that
influence its absorption, distribution and metabolism and the subsequent fluctuations in its
plasma level. For the first months or years, of therapy, the honeymoon period, LD provides a
stable improvement. Later, the effect wears off a few hours following intake, with resultant
periods of on and off fluctuations in relation to the peripheral LD concentration. PD patients
can  also  experience choreiform movements  occurring  typically  at  peak  blood  LD  levels
(peak-dose dyskinesia). Less characteristic, dyskinesia can also occur at decreasing blood LD
levels (end-of-dose dyskinesia). The therapeutic window of LD narrows in time and MCs are
more likely to occur seemingly unrelated to medication intake. 
Under physiological conditions, dopaminergic neurons store and regulate the release
of  dopamine,  and the  dopaminergic  receptors  are  exposed to  relatively constant  levels  of
dopamine  [51]. In the PD patient, oral substitution therapy is considered to be one of the
major factors contributing to the pulsatile stimulation of the receptors, due to the short T1/2
[52]. As the disease progresses, the number of striatal neurons decreases and there are fewer
neurons capable to buffer a short-acting dopaminergic agent. The loss of striatal dopaminergic
neurons  and  the  dysregulation  of  the  events  following  the  receptor  binding  cause  the
dependence of the striatal dopamine concentration and of dopaminergic stimulation on the
plasma LD level, which in turn is dependent on the LD intake [53]. 
Exposure  of  dopamine  receptors  to  fluctuating  neurotransmitter  levels  causes
discontinuous or pulsatile stimulation, which is presumed to be responsible for the MCs [54].
It has been postulated that such pulsatile stimulation causes hypersensitivity of the striatal
dopamine  receptors.  It  induces  molecular  changes  in  the  striatal  neurons  and
neurophysiological changes in the outputs which underlie motor fluctuations and dyskinesias
[55].  It  has  been  proposed  that  previous  exposure  to  LD,  i.e.  LD priming increases  the
susceptibility  to  the  development  of  dyskinesias  [52] and  in  this  respect  the  pulsatile
activation  of  D2  dopamine  receptors  is  considered  to  be  most  strongly  involved  [56].
Continuous  stimulation  of  the  dopaminergic  receptors  has  been  presumed  to  cause  less
fluctuation and dyskinesia [57]. 
The  continuous  dopaminergic  stimulation  (CDS)  hypothesis  explained  the
development of MCs as a consequence of a short LD T1/2. This theory is falling out of favor,
because  studies  with  longer-acting  dopaminergic  preparations  showed  no  significant
differences in the occurrence of dyskinesias  [58] and could not explain their development
based  on  the  short  T1/2 of  the  preparations  used.  In  animal  models,  a  continuously
administered short-acting dopamine agonist (apomorphine) caused less dyskinesia [59]. This
means that a short-acting dopaminergic medication, which according to the CDS hypothesis
would cause more dyskinesias, if delivered continuously, lowers the risk of MCs. The CDS
has recently been replaces by the continuous dopaminergic delivery (CDD) concept, CDD
having the goal of reducing MCs by delivering a drug in a constant manner, regardless of its
T1/2 [60]. 
Several approaches aiming to provide a more continuous plasma levodopa level and
thereby to reduce motor complications have been developed. In everyday clinical use, in order
to treat motor complications LD doses can be divided throughout the day, ER formulations are
available, or a dopamine-metabolizing enzyme inhibitor, such as a COMT inhibitor can be
added. Amantadine has also proved efficacy in the treatment of dyskinesias and new delivery
technologies, such as the LCIG therapy and the apomorphine subcutaneous pump are now
available. 
Table 2. Levodopa side-effects
Cardiac
 orthostatic hypotension
 arrhythmia due to the beta-adrenergic effect 
of dopamine and other levodopa metabolites. 
Central nervous system
 mental changes
 depression
 euphoria
 paranoid thoughts
 psychosis, hallucination, delusion
 confusion
 insomnia, nightmares
 anxiety, agitation
 general feeling of discomfort
 tiredness
 clumsiness
 blurred vision
Gastrointestinal
 anorexia
 nausea
 vomiting
 abdominal pain
 constipation
 bleeding and perforation of peptic ulcers
Hematologic* 
 hemolytic anemia
 agranulocytosis
 leucopenia
elevation of 
 blood urea nitrogen
 SGOT, SGPT, LDH, bilirubin, alkaline 
phosphatase, protein-bound iodine, 
decreased prolactin
 it acts on the adenohypophysis and stimulates
the release of prolactin inhibitory factor.
Urinary
 Loss of bladder control
 Difficult urination
Dermatological
 Skin rash
 Swelling of feet or lower legs
Several of the listed side-effects are meanwhile non-motor symptoms of PD, for example 
constipation, depression, anxiety or hypotension. 
It is necessary to carry out periodic evaluations of hepatic, hematological and renal 
functions in patients taking LD
1. LCIG treatment avoids  the variability of  plasma levels due to  impaired gastric
emptying and the breakdown of LD by the gastric juice. Due to the by-passing of the gastric
emptying, there is a significant smoothing of the plasma LD level and a reduction of the
response fluctuations [2]. In a study on 19 patients [61], the full plasma concentration versus
time profiles of LD, carbidopa and 3-O-methyldopa were evaluated.  LD rapidly achieved
therapeutic  plasma  levels,  which  were  constant  during  the  infusion.  A small  peak  was
observed during the first 3 h of infusion after the morning dose, and another due to the slower
absorption of carbidopa. Meals also caused small fluctuations in the plasma LD level, which
were  8.3  and  3.7-fold  less  than  those  with  immediate  release  (IR)  and  ER  preparations,
respectively. After the infusion, the plasma LD level decreased rapidly. The absolute LCIG
bioavailability  was  estimated  to  be  88%  in  one  analysis,  which  is  comparable  to  that
following oral administration [62]. 
LCIG treatment is delivered via a percutaneous endoscopic jejunostomy and a portable
infusion pump. The pump is easy to use, but there is a considerable demand for caregiver
burden, because patients in an advanced disease stage can exhibit severe motor fluctuations,
off periods and dyskinesias, when they are unable to adjust the parameters of the pump [63].
Technical problems can occur that are related to the jejunostomy tube, but more troublesome
ones can arise from the surgical procedure, such as secretion, infections and inflammation at
the site of the PEG/PEJ tube [64]. Tolerance has been revealed in experimental studies [65].
An axonal polyneuropathy, often associated with vitamin B deficiency can occur with this
procedure,  which  may  be  explained  by  the  impaired  absorption  of  vitamins  and  the
interference of LD with the vitamin B12 metabolism [66, 67]. A 24 h delivery has the risk of
LD toxicity and psychosis,  because of which most patients  are advised to stop the pump
overnight.  In  a  large  open  label  trial,  no  patients  were  reported  to  develop  visual
hallucinations or psychosis [68]. The high cost limits wide-scale use of this therapy.
Table 3. Drug interactions 
Drug Effect on LD Result of interaction
pyridoxine enhances peripheral metabolism of LD increases the LD side-effects due to 
excessive peripheral decarboxylation
dopamine receptor 
antagonists
block the symptomatic effect of LD decrease the symptomatic effect of LD
nonspecific MAOIs unpredictably interfere with 
catecholamine inactivation
augment the central effects of levodopa
hypertensive crisis and hyperpyrexia
anticholinergics slow gastric emptying can reduce absorption of levodopa.
amantadine
AADC inhibitors
atropine
amphetamine.
various mechanisms enhance the LD effect
antihypertensives reduce blood pressure increase hypotension
anesthetics
 cyclopropane
 halothane
sympathomimetics
 epinephrine
 isoprenaline
various mechanisms worsen cardiac side-effects of LD, such as 
arrhythmias
propranolol beta-adrenergic blocker enhances LD action on tremor
diminishes cardiac side-effects of LD
LD: levodopa, MAOIs: monoamine oxidase inhibitors, AADC: amino acid decarboxylase
2. ER formulations are another option through which to provide more continuous LD
plasma levels. The ER formulations pose the same long-term dyskinesia risk as the standard
formulation,  and no superiority in controlling motor fluctuations  [17].  Their  absorption is
erratic, and the plasma levels are unpredictable, which ultimately results in dose failures and a
delay in clinical benefit [69]. 
An  investigational  ER  carbidopa-LD  (CD-LD)  formulation  (IPX066)  is  currently
undergoing a phase III clinical trial. This tablet contains CD-LD microbeads that dissolve at
different rates in the small intestine. The results indicate rapid absorption, with an onset of
effect similar to that for the IR formulation, more sustained therapeutic plasma levels and a
longer duration of clinical benefit [70]. The initial absorption rate is similar to that of the IR
formulation. The plasma LD concentration is more sustained, remaining above 50% of Cmax
for 4 h with IPX066 as compared with 1.4 h for IR. The plasma LD concentration fluctuation
index evaluated on day 8 was more than 50% lower and the mean Cmax/Cmin LD ratio was
more than 7-fold lower with IPX066 than with IR [71]. In a randomized, 13-week, blinded III
study of 393 patients, IPX066 reduced the off time by an average of 1.17 h more than IR [72]. 
Although LD from IPX066 is 74.5% bioavailable, patients needed a higher total daily dose in
the IPX066 period relative to the IR period. The LD dose accumulates and there might be a
risk of MCs at high doses  [73]. However, since this high dose is delivered in a continuous
form, maintaining a steady-state plasma concentration, it is conceptually different from a high
dose given in a pulsatile manner. Theoretically, therefore there is no higher risk of dyskinesia
and motor fluctuations and the reduction in dyskinesia is an effect on the central therapeutic
window [74, 75].
3. Intravenous LD infusion is not appropriate for chronic treatment, though it can
reduce severity and incidence of dyskinesias, whereas the transdermal and transnasal routes of
delivery are under investigation, but have not yet reached the market [17].
II. Other dopaminergic medication 
1. MAO-B inhibitors and their effects on the metabolism and efficacy of LD
Selegiline and rasagiline are selective irreversible MAO-B inhibitors [76] that reduce
dopamine breakdown, improve the dopamine deficiency symptoms and potentiate the effect
of LD. The presumed neuroprotective effect has not been proved so far [77]. Due to loss the
of selectivity for MAO-B at higher doses, at which inhibition of MAO-A can also occur, there
is a risk of tyramine-induced hypertension, i.e. the cheese effect. 
1.1.Selegiline has an extensive first-pass metabolism to amphetamine metabolites. Its
oral bioavailability is about 25% in mice  [78] and 10% in humans  [79]. Two-thirds of the
metabolite recovered from the urine is (R)-metamphetamine, formed by N-depropargylation.
Other  metabolites  are  desalkylated  ones,  further  converted  by  para-hydroxylation  and
excreted  as  conjugates,  and  the  recently  described  selegiline-N-oxide.  Some  are
pharmacologically  active  and  are  responsible  for  the  psychomotor  stimulant  and
cardiovascular  side-effects.  The  orally-disintegrating  (ODT)  form  overcomes  this
pharmacokinetic problem. It  has an improved bioavailability,  allows a dose reduction and
results in lower exposure to amphetamine metabolites. About 30% is absorbed in the mouth,
while further absorption occurs in the GI tract, leading to a higher AUC value. There are no
significant  differences  in  AUC and  Cmax for  the  conventional  and  the  ODT formulation.
Unfortunately,  the  improved  pharmacokinetic  profile  is  not  accompanied  by a  significant
clinical  improvement  and the efficacy and safety profiles  are  comparable  to  those of  the
conventional  formulation.  The transdermal  formulation is  used for  the treatment  of  major
depression [80].
1.2.Rasagiline is  a  second-generation  propargylamine  pharmacophore,  that  breaks
down dopamine to DOPAC and HVA and acts in the deamination of beta-phenylethylamine
which stimulates the release of dopamine and inhibits the neuronal reuptake of dopamine. The
result is an elevation of the dopamine concentration in the synaptic cleft. Its bioavailability is
36%. The dose linearity and proportionality for Cmax and AUC are consistent. A high-lipid
meal reduced Cmax and AUC. Plasma protein binding is 60-70%. Its hepatic biotransformation
is extensive, but the metabolites are inactive and no extrahepatic clearance has been found.
There are increases in Cmax and AUC in patients with hepatic failure, and it should therefore
not be administered to those patients  [81]. The mean T1/2 is 1.34 hours, but this does not
correlate  with  the  symptomatic  effect,  because  it  irreversibly  blocks  MAO-B  and  the
restoration of MAO-B activity depends on the regeneration of the enzyme, which was shown
in a PET study to be around 40 days [82]. 
Rasagiline interacts with the CYP450 system. Administration of a CYP1A2 inhibitor
such as ciprofloxacine,  cimetidine or  fluvoxamine increases  the AUC of rasagiline,  while
CYP1A2 inducers, such as omeprazole, may reduce it. When added to LD, it may increase
dyskinesias, but the difference is not significant.  Patients receiving an oral challenge with
tyramine in the TEMPO and PRESTO studies did not exhibit any significant increase of blood
pressure [83]. Co-administration with agents enhancing serotonin levels, such as SSRI, SNRI,
cyclic antidepressants or serotoninergic opioids, raises the concern of a risk of inducing the
serotonin-like  syndrome,  and  should  therefore  be  avoided,  though  this  risk  could  not  be
confirmed for antidepressants co-administered with rasagiline [84]. A meta-analysis based on
the Medline and the Cochrane Library database demonstrated that rasagiline reduces motor
scores in early PD, and reduces the  off-time when added to LD in more advanced patients.
The neuroprotective effect could not be proved in the delayed-start studies [85].
2. Dopamine agonists
Dopamine agonists (DAs) can be used as monotherapy in early PD, or as an add-to LD
in advanced disease. There are two categories of these drugs: ergot-derived which act on D2
and D1 dopamine receptors and on some serotonin and adrenergic receptors and the non-
ergot-derived  compounds,  such  as  pramipexole  and  ropinirole,  which  act  on  D3  and D2
receptors. DAs directly stimulate the intact postsynaptic receptors in the striatum. There is no
need for metabolic transformation for these drugs to gain effectiveness. They have a longer
T1/2 than that of LD (6 and 8 hours for ropinirole and pramipexole, respectively) and provide a
more prolonged stimulation of the receptors than I n the case of LD. Another advantage is
their selectivity to certain dopaminergic receptors, whereas LD stimulates all subtypes. DAs
reduce  LD  metabolism  and  the  generation  of  free  radicals,  and  might  therefore  be
neuroprotective  [86]. Their effects on the non-motor symptoms of PD, such as depression,
have also been shown [63]. 
The DAs offer a good antiparkinsonian effect and a lower risk of MCs, but several
troublesome non-motor side-effects can occur, such as nausea, orthostatic hypotension, sleep
attacks, REM sleep disorder, psychosis and impulse-control disorder [87]. As compared with
LD, DAs cause less dyskinesia, but when used as monotherapy, relative to placebo they have
consistently  been  associated  with  more  dyskinesia  (5-10%)  [52,  88].  In  some  studies,
dyskinesia was also seen in the placebo groups, suggesting that other factors, not related to the
DAs  can  contribute  to  their  development.  Pramipexole  treatment  increased  LD-induced-
dyskinesia (LID) and its severity and duration and it is therefore presumed that the effect on
LD is more than a simple additive effect  [89]. In one study pramipexole-receiving patients
displayed a slightly higher incidence of dyskinesia than that in the rotigotine group and both
with a higher incidence in comparison with placebo (15% and 12% vs 3%) [90]. The on time
with no troublesome dyskinesias was significantly higher in the active treatment groups and
no differences between pramipexole and rotigotine were observed. There is no evidence that
pramipexole-related  dyskinesias  might  be  dose-dependent.  No  differences  were  found
between the dyskinesia rates caused by ergot-derived and non-ergot DAs [91]. 
In order to provide a more continuous stimulation of the dopaminergic neurons, three
approaches  are  available  in  this  class  of  medication:  the  apomorphine pump,  transdermal
administration for rotigotine and ER formulations. The latter are available for both ropinirole
and pramipexole.  There is  better  compliance for ER preparations administered once daily
[63]. The ER formulations provide a prolonged T1/2 and steadier plasma levels. In comparison
with the IR formulation Cmax and Cmin and AUC for the same daily dose were equivalent [92].
Clinical  trials  revealed  only  the  non-inferiority  of  pramipexole  ER  as  compared  to  IR
formulations; ER preparations did not cause higher rates of dyskinesia [93].
2.1. The apomorphine pump. Apomorphine is a water-soluble DA that is active on D1
and D2 receptors. It can be used as a subcutaneous injection delivered by a pen injector for
acute treatment in the  off periods, or as a continuous subcutaneous infusion. The onset of
action is rapid: 5-15 min.  T1/2 is 40 min.  The effect is seen between 40 and 90 min. The
characteristic side-effect is nausea, and therefore an antiemetic such as trimethobenzamide or
domperidone is recommended before treatment and can be slowly tapered off. Several studies
have shown efficacy of subcutaneous apomorphine therapy. There are few interferences with
other antiparkinson medication. Long-term therapy does not cause any delay in the onset of
action, and there is no need for dose changes during therapy [94]. 
Apomorphine has been also tried in a sublingual form  [95]. Subcutaneous infusion
needs pretreatment with an antiemetic. As monotherapy, high doses would be needed, but are
usually  not  tolerated.  Oral  LD  supplementation  is  therefore  needed,  which  modifies  the
continuous receptor stimulation effect of apomorphine infusion through a pulsatile stimulation
effect. Other side-effects of apomorphine include subcutaneous nodules (70%), somnolence
(10%),  renal  impairment,  orthostatic  hypotension,  impulse  control  disorder  and psychosis
[64]. 
2.2. Rotigotine is a non-ergot-derived DA with activity on dopamine D1 through D5
receptors, and in particular on D3 receptors, as well as on adrenergic and serotoninergic sites.
It has a convenient once-daily administration. It is contained in a silicone-based matrix for
transdermal  delivery,  which  provides  continuous  drug  release  and  stable  plasma
concentrations over a period of 24 h [96]. Clinical studies have shown the efficacy and safety
of the rotigotine transdermal patch in the treatment of early and advanced PD [97] and in RLS
[98]. An overnight switch from an oral DA to rotigotine patch was effective and well tolerated
in clinical studies [99]. 
The plasma concentration increases within 16 h after transdermal administration, and
falls  considerably at  12 hours after  patch removal.  The mean apparent dose proved to be
61.4% of  the  total  drug  content  of  the  patch.  The  absolute  bioavailability  measured  for
transdermal  administration was 37%. In view of  the apparent  dose of 61.4% of the dose
applied, this means that more than 60% of the dose absorbed is bioavailable. T1/2 after removal
of  the  patch  was  5.3  h.  The  pharmacokinetic  parameters  for  rotigotine  intravenous  and
transdermal  administration  exhibited  a  similar  Cmax and  decreasing  profile  following  the
termination of drug delivery [100].
The  products  of  the  oxidative  metabolism of  rotigotine  are  rapidly  conjugated  to
glucuronides  or  sulfates,  as  shown  in  animal  models  and  humans  [101].  The  phase  1
metabolites have high affinity for dopamine receptors, but a very low plasma level, whereas
the phase 2 conjugates have practically no affinity. After transdermal administration of radio-
labeled rotigotine, 66% was eliminated through the kidney and less through the feces, with a
total of 88% of the radioactive dose recovered within 96 h [102]. The renal elimination of the
unchanged compound was below 1%. Under steady-state conditions, the mean unconjugated
and the total plasma rotigotine concentrations increased in a dose-proportional manner. The
ratio of rotigotine to unconjugated rotigotine was identical at all evaluated doses  [99]. The
bioavailability of rotigotine can present irregularities due to the unstable absorption caused by
an improper placement of the patch or by sweating.  Problems of absorption arose due to
crystal formation in the patches, and this led to temporary withdrawal of the product from the
US market.  Rotigotine  is  generally  well  tolerated.  The most  common adverse  events  are
application-site reactions, GI disturbances, somnolence and headache [95].
III. Non-dopaminergic medication
A broad variety of non-dopaminergic medicaments have been trialed and used in PD,
ranging  from  vitamin  D,  coenzyme  Q,  caffeine,  nicotine,  through  antiepileptics  such  as
safinamide and zonisamide or anticholinergic agents, to cannabinoid receptor antagonists or
metabotropic glutamate receptor ligands (Table 4) [103]. 
Several trials that are still ongoing are investigating the effects of nondopaminergic
agents  such  as  adenosine  A2A antagonists,  a2-adrenergic  receptor  antagonists,  5-HT1A-
receptor agonists and compounds acting on the glutamatergic system, on motor symptoms,
motor fluctuations and dyskinesias in PD [104]. Safinamide has MAO-B inhibitor properties
and a complex mechanism of action. It might be effective as an add-on treatment to DA for
early PD [105]. Adenosine A2A receptor antagonists, studied in several clinical trials, showed
effectiveness in improving the motors symptoms during the  on period and in reducing the
length of the  off period, without severe side-effects  [106].  A synergistic dopaminergic and
glutamatergic  dysfunction  has  been  revealed  in  PD,  and  targeting  of  the  glutamatergic
transmission is therefore a promising approach in PD therapy [107]. 
The main excitatory amino acid in the brain is glutamate. An enhanced release and a
prolonged stimulation of the glutamate receptors cause damage to the postsynaptic neurons.
Glutamate-induced excitotoxicity can cause a self-maintained cascade of events, such as free
radical  generation  and  Ca2+ overload  and  is  linked  with  a  mitochondrial  dysfunction.
Glutamate  receptors  in  the  CNS are  the  fast-acting  ionotropic  receptors  (the  AMPA,  the
NMDA and the kainate receptors), coupled with sodium or calcium ion channels and the slow
modulatory  metabotropic  receptors  (mGluRs),  coupled  with  G-protein  [44].  Enhanced
glutamatergic activity in the striatum underlies peak-dose dyskinesia. This increases activity
in the D1-mediated direct striato-pallidal pathway, consequently inhibits basal ganglia output
and causes dyskinesia. LD use has been shown to be associated with specific changes in the
distribution  and  expression  of  NMDA receptor  subunits.  In  this  respect  an  association
between  LID  and  changes  in  the  distribution  of  NR2B  subunits  from  a  synaptic  to  an
extrasynaptic location has been found, suggesting that LD in PD does not normalize basal
ganglia function, but shifts it to a different, still not normal state [65]. Glutamate antagonists
might improve PD symptoms, reduce excitotoxicity, exert a neuroprotective effect [108], and
might reduce dyskinesia, the latter by reducing the cortico-strial glutamatergic input in the
direct pathway neurons.  Some of the medication already in use for PD treatment such as
anticholinergics  and  amantadine,  have  an  antiglutamatergic  activity.  NMDA antagonists,
especially those capable of blocking the NR2B subunit showed anti-parkinsonian and anti-
dyskinetic effect in animal models, but not in clinical trials. Accordingly, in a large meta-
analysis  NMDA antagonists  significantly  reduced  severity  of  dyskinesias  as  compared  to
placebo, but had no significant effect on motor function [109].  In this class of compounds,
more detailed results of research on kynurenines will be presented.
Kynurenines
One of the metabolic pathways for tryptophan is the kynurenine pathway (Figure 2).
This is responsible for the production of nicotinamide adenine dinucleotide and nicotinamide
adenine dinucleotide phosphate. The central compound of this pathway is L-kynurenine (L-
KYN), which can be metabolized in the brain in two ways, either to kynurenic acid (KYNA)
or to 3-hydroxy kynurenine (3-OH-L-KYN) and quinolinic acid (QUIN). These metabolites
have neuroactive properties, as shown in experimental studies [110-114]. 
The key enzyme of the kynurenine pathway, kynurenine aminotransferase II (KATII)
transforms L-KYN to KYNA through an irreversible transamination. The reduction of KATII
activity  caused  a  depletion  of  KYNA in  animal  models.  KYNA is  an  NMDA receptor
antagonist,  a  kainate/AMPA receptor  antagonist  and  an  inhibitor  of  the  presynaptic  α7
nicotinic acetylcholine receptors and has shown neuroprotective properties in animal models. 
In contrast, 3-OH-L-KYN and QUIN exert neurotoxic properties. QUIN is localized to
glia and immune cells. It is a specific competitive agonist of NMDA receptors presenting the
NR2A and NR2B subunits. Through activation of these receptors, QUIN causes the release
and  inhibits  the  uptake  of  endogenous  glutamate,  and  induces  lipid  peroxidation  and
production of reactive oxygen species. The result is excitotoxicity, an axon-sparing neuronal
loss, and damage to the striato-pallidal encephalinergic neurons. 3-OH-L-KYN causes free
radical production. The neurotoxic effect is due in part to a metabolite, 3-hydroxyanthranilic
acid. 
In patients with PD, there is evidence of an alteration of the kynurenine pathway. It has
also been shown that the neuroprotective intermediates are reduced in some brain regions and
in the serum, whereas the levels of 3-OH-L-KYN and QUIN are elevated and the level of
KAT is reduced. An altered KYNA metabolism in PD is indicated by the measurement of
metabolites  in  the  red  blood cells  and plasma of  patients  [115]. The result  of  an  altered
kynurenine metabolism is over-excitation of the glutamate receptors, with consecutive cell
damage  therefore an intervention in the kynureninne pathway may have a neuroprotective
effect and may alleviate LID [116-118]. 
Figure 2. Kynurenine pathway
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Conclusions
The  gold  standard  of  PD  therapy  is  levodopa.  The  characteristics  of  its
pharmacokinetics are a short T1/2, absorption through active transport in the small intestine
and at the BBB, an extensive peripheral metabolism and renal elimination of the metabolites.
There are a number of factors that influence the absorption of levodopa, and thereby cause
irregularities in its therapeutic effect, such as DGE, or the competition for the absorption sites
in the small bowel. ER formulations and LCIG therapy provide a more stable plasma level. As
compared with levodopa, DAs have a longer T1/2 and a more stable pharmacokinetic profile.
Attention  is  focused  on  the  development  of  non-dopaminergic  medication  and  on  the
development  of neuroprotective agents,  among which,  neuroactive kynurenines  have been
studied for their antiglutamatergic properties.
Expert opinion
Levodopa is practically unavoidable in the advanced stages of the disease. A good
pharmacokinetic profile is of even more important in these stages of the disease, when the
fluctuating  plasma  levodopa  levels  can  not  be  buffered  by  the  decreasing  number  of
functional dopaminergic neurons. This is when dopaminergic stimulation becomes dependent
on the plasma levodopa level. The CDS concept postulates that a short T1/2 is one of the major
factors  contributing  to  pulsatile  dopamine  receptor  stimulation  and  the  development  of
dyskinesias. 
Some of the motor fluctuations that are observed in the more advanced stages of the
disease are at least partly explained by the irregular ADMET properties of the drug. Motor
fluctuations such as  delayed-on,  no-on and unpredictable  off phenomena are explained by
bioavailability alterations due to GI involvement in the later stages of the disease. 
SIBO  and  HP  infection  are  common  problems  among  advanced  PD  patients,
contributing to diminished levodopa absorption and to worsening of the (unpredictable) motor
fluctuations. Little can be done with these problems for a patient on oral therapy. Certain
dietary changes can improve absorption. Infection with HP and SIBO are treatable conditions
that should be taken into account in the management of advanced-stage patient exhibiting a
poor therapeutic response. 
Levodopa dosing should be carefully divided throughout the day, and patients should
receive advice as concerns medication intake and a proper diet, such as a low-protein intake
when taking levodopa and high-fiber diet to improve constipation. 
Other dopaminergic agents that influence levodopa breakdown can be co-administered
in order to minimize the peripheral side-effects or to reduce MCs. These include COMT and
MAO-B inhibitors,  which should be chosen on an individual patient basis  with regard to
pharmacokinetic profile, age and possible side-effects. 
It is mandatory to provide the best possible individualized levodopa therapy for each
patient,  with  attention  to  ensuring  optimal  absorption,  providing  smooth,  continuous
stimulation of the dopaminergic neurons, avoiding especially high plasma levels, considered
to be a  high risk for the development  of  dyskinesia.  In order  to  accomplish this,  a  good
knowledge of the pharmacokinetics of the medication used, the possible interactions and the
side-effect profile is essential. 
Among  DAs  apomorphine  pump,  transdermal  rotigotine  and  ER  formulations  are
approaches through which to provide a more constant stimulation of the dopamine receptors,
but have limitations due to their side-effect profile.
In  the  last  few  years,  there  have  been  no  substantial  changes  in  the  field  of
dopaminergic agents, but there is now a better understanding of their mechanism of action and
of the dopamine metabolism, and the current aspects and targets have been outlined with a
view to improving symptomatic control, and minimizing side-effects. The CDS hypothesis
stipulates  that  medication  with  a  longer  T1/2,  which  ensures  smooth  absorption,  a  less
fluctuating  plasma  level  and  transport  through  the  BBB,  could  achieve  non-pulsatile
stimulation of the dopamine receptors and minimize the long-term side-effect of levodopa
therapy, whereas the CDD concept postulates that continuous delivery is the mainstay of the
therapy.  With  regard  to  the  CDD  concept,  in  order  to  improve  delivery,  enhance
bioavailability and reduce plasma level fluctuations, ER formulations and an intra-intestinal
delivery system have been introduced in clinical practice.
LCIG  therapy  avoids  several  of  the  problems  caused  by  DGE.  It  provides  more
continuous absorption and consequently steadier levodopa blood levels, a continuous delivery
and hence, presumably, a more continuous stimulation of the striatal neurons. Its use is limited
by the need for a surgical procedure and high costs. There are other aspects that must be borne
in mind, such as the possibility of polyneuropathy development due to a combined B12/B6
vitamin deficiency, and the risks of technical problems with the pump, and local infections.
There also is the dependency on a caregiver to start the pump in the morning hours, or to
deliver an extra dose in an  off state, if the patient is unable to initiate it. Difficulty is also
caused by the large size of the pump, which is inconvenient for many patients. Continuous
transdermal levodopa delivery would be a solution for these inconveniencies. 
Attention has lately focused on the non-motor symptoms, which can manifest even in
the early stages of the disease and have a great impact on the quality of life of the patients.
Non-dopaminergic pathways also play a role in their occurrence. These problems and their
treatment  could  not  be  discussed  in  this  review,  for  reasons  of  space.  More  attention  is
focused  on  the  development  of  non-dopaminergic  medication,  on  alleviation  of  the  very
troublesome non-motor symptoms and on the development of putative neuroprotective agents.
Among these latter, neuroactive kynurenines have been studied for their glutamate antagonist
properties; they have been shown to exert antidyskinetic effects in animal models, and their
properties suggest that they could also provide a neuroprotective effect in patients with PD.
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